Ignite Creation Date:
2024-05-06 @ 5:48 PM
Last Modification Date:
2024-10-26 @ 2:36 PM
Study NCT ID:
NCT05439044
Status:
UNKNOWN
Last Update Posted:
2022-07-08
First Post:
2022-06-27
Brief Title:
A Real-World Study of Anti-SARS-CoV-2 Monoclonal Antibodies
Sponsor:
Assistance Publique - Hôpitaux de Paris
Organization:
Assistance Publique - Hôpitaux de Paris
Study Overview
Official Title:
A Real-World Study of Anti-SARS-CoV-2 Monoclonal Antibodies in Patients at High Risk of Severe Forms of Covid-19
Status:
UNKNOWN
Status Verified Date:
2022-06
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
COVIMAB
Brief Summary:
Absence of anti-SARS-CoV-2 vaccine response or insufficient vaccine response may occur in immunocompromised patients Being at high risk of a severe form of Covid-19 they may be eligible to receive recombinant anti-SARS-CoV-2 monoclonal antibodies mAbs This study aims to describe patients who received anti-SARS-CoV-2 mAbs in prophylaxis andor curative of covid-19 and to analyze the hospitalization and mortality rates This study is multicentric on all the university hospitals of Paris AP-HP
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None